Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

A Phase 1a/b Dose Escalation Study of Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD

Blood (2019) 134 (Supplement_1): 5148.

https://doi.org/10.1182/blood-2019-129685

Published: 2019

Journal Articles

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Qiujun Shao, Simran Tiwana, Nicholas Despiegel, Franziska Dirnberger

Blood (2019) 134 (Supplement_1): 5814.

https://doi.org/10.1182/blood-2019-126309

Published: 2019

Journal Articles

A Patient-Centred Approach to Understanding the Trade-Offs Associated with Treatment Decision Making in Hematological Cancers with Short Life Expectancy

Chloe Johnson, Timothy J Bell, Kate Sully, PhD, Verna L Welch, PhD MPH, CPEHR, CPHIMS, Francois Peloquin, BS, Adam Gater

Blood (2018) 132 (Supplement 1): 5899.

https://doi.org/10.1182/blood-2018-99-116226

Published: 2018

Journal Articles

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Rüdiger Hehlmann, MD, Michael Lauseker, PhD, Susanne Saussele, MD, Markus Pfirrmann, Stefan W. Krause, MD, Hans-Jochem Kolb, MD, Andreas Neubauer, MD, Dieter K. Hossfeld, Christoph Nerl, MD, Alois Gratwohl, MD, Gabriela M. Baerlocher, Dominik Heim, MD, Tim Henrik Bruemmendorf, Alice Fabarius, PhD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martin C. Müller, MD, Sabine Jeromin, PhD, Ulrike Proetel, PhD, Katharina Kohlbrenner, PhD, Astghik Voskanyan, PhD, Sébastien Rinaldetti, Wolfgang Seifarth, PhD, Birgit Spiess, Leopold Balleisen, MD, Maria E Goebeler, MD, Mathias Hänel, MD, Anthony D. Ho, MD, J Dengler, C Falge, Lothar Kanz, MD, Claus-Henning Köhne, MD, PhD, Andreas Burchert, MD, Michael Kneba, MD PhD, Frank Stegelmann, MD, C Köhne, Hans-Walter Lindemann, C Waller, Michael Pfreundschuh, MD, Karsten Spiekermann, Wolfgang E Berdel, MD, L Müller, Matthias Edinger, MD, Jiri Mayer, Prof, MD SCs, Dietrich W Beelen, MD PhD, Martin Bentz, MD, Hartmut Link, MDPhD, Bernd Hertenstein, MD, R Fuchs, Martin Wernli, MD, F Schlegel, Rudolph Schlag, M de Wit, Lorenz Trümper, MD, H Hebarth, M Hahn, Jörg Thomalla, MD, Christof Scheid, MD, Philippe Schafhausen, MD, Walter Verbeek, MD, Michael J. Eckart, MD, Winfried Gassmann, MD PhD, Antonio Pezzutto, MD, Michael Schenk, Peter Brossart, MD, Thomas Geer, MD, Stephan Bildat, E Schäfer, Andreas Hochhaus, MD, Joerg Hasford

Blood (2017) 130 (Supplement 1): 897.

https://doi.org/10.1182/blood.V130.Suppl_1.897.897

Published: 2017

Journal Articles

Life Expectancy in Long-Term Survivors Transplanted for Myelofibrosis: A Registry Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Blood (2017) 130 (Supplement 1): 3307.

https://doi.org/10.1182/blood.V130.Suppl_1.3307.3307

Published: 2017

Journal Articles

Risk Differential in Inhibitor Development in the First Days of Treatment By Product Class: A Sippet Analysis

Flora Peyvandi, MD PhD, Antonino Cannavò, MD, Isabella Garagiola, PhD, Roberta Palla, PhD, Frits Rosendaal, MD PhD, Piermannuccio Mannucci, MD

Blood (2016) 128 (22): 330.

https://doi.org/10.1182/blood.V128.22.330.330

Published: 2016

Journal Articles

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

Mark W. Drummond, PhD MD, Daniel J. DeAngelo, MD PhD, Michael W. Deininger, MD PhD, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Albert Thomas Quiery, MD, Elizabeth O Hexner, MD, Hongliang Shi, MS, Terri Alvarez-Diez, PhD, Erica K. Evans, PhD, Mary Ellen Healy, MS, Beni B. Wolf, MD PhD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 477.

https://doi.org/10.1182/blood.V128.22.477.477

Published: 2016

Journal Articles

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Michael J. Kelly, MD MPH, MS, Susan K Parsons, MDMRP, David C. Hodgson, MD, Joshua T Cohen, PhD, Jennifer M Yeh, MD PhD, Jeremy S. Abramson, MD, Debra L. Friedman, MD MS, Tara O Henderson, MDMPH, Peter W Johnson, MD, Stephen G Pauker, MD, John M. Raemaekers, MD PhD, Jane N. Winter, MD, Kara M. Kelly, MD, Ralph M. Meyer, MD, Sharon M Castellino, MD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 2635.

https://doi.org/10.1182/blood.V126.23.2635.2635

Published: 2015

Journal Articles

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

Corrado Tarella, MD, Angela Gueli, Federica Delaini, Anna Maria Barbui, MD, Riccardo Bruna, Daniele Caracciolo, Daniela Gottardi, Giuseppe Gritti, MD, Roberto Passera, PharmD, PhD, Safaa Ramadan, PhD MD, Andrea Rossi, MD, Alessandro Rambaldi, MD

Blood (2015) 126 (23): 3989.

https://doi.org/10.1182/blood.V126.23.3989.3989

Published: 2015

Journal Articles

"Post-Pulmonary Embolism Syndrome" after a First Episode of PE: Results of the E.L.O.P.E. Study

Susan R Kahn, MD MSc, Andrew Hirsch, MD, Margaret Beddaoui, MSc, Arash Akaberi, MSc, David Anderson, MD, Philip S Wells, MDMSc, Marc Rodger, MD MSc, Susan Solymoss, MD, Michael J. Kovacs, MD, Lawrence Rudski, MD, Avi Shimony, MD, Carole Dennie, MD, Chris Rush, MD, William H. Geerts, MD, Paul Hernandez, MD, Shawn Aaron, MD, John T Granton, MD

Blood (2015) 126 (23): 650.

https://doi.org/10.1182/blood.V126.23.650.650

Published: 2015

Journal Articles

Quality of Life Survey in Nonmyeloablative Bone Marrow Transplant Patients at a Large Academic Center

Harsh Shah, DO, Robert Nelson, MD, Jose Azar, MD

Blood (2015) 126 (23): 5612.

https://doi.org/10.1182/blood.V126.23.5612.5612

Published: 2015

Journal Articles

Impact Of Dedicated CML Clinic On The Outcome Of Patients With Newly Diagnosed CML: Experience Of a Single Canadian Center

Moussab Damlaj, BSc MD, Yury Monczak, PhD, Sarit Assouline, MD

Blood (2013) 122 (21): 5186.

https://doi.org/10.1182/blood.V122.21.5186.5186

Published: 2013

Journal Articles

Individual Patient Data Of Conditional Survival Analysis In a Large Cohort Of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way To Identify Patients With Extended Life Expectancy

Martina Kleber, Stefanie Hieke, Milena Pantic, Bernd Koch, Gabriele Ihorst, Ralph Waesch, MD, Philippe Moreau, MD, Martin Schumacher, Monika Engelhardt, MD

Blood (2013) 122 (21): 1745.

https://doi.org/10.1182/blood.V122.21.1745.1745

Published: 2013

Journal Articles

Estimating Long-Term Life Expectancy in Philadelphia Chromosome Positive (Ph+) Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results of A Microsimulation Model

Sonya J Snedecor, PhD, Xiang Ji, MS, Matthew Magestro, Andrew M Stein, PhD, Marc Botteman, MSc, MA

Blood (2012) 120 (21): 4441.

https://doi.org/10.1182/blood.V120.21.4441.4441

Published: 2012

Journal Articles

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2012) 120 (21): 3794.

https://doi.org/10.1182/blood.V120.21.3794.3794

Published: 2012

Journal Articles

Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy

Martina Kleber, Stefanie Hieke, Bernd Koch, Gabriele Ihorst, Ralph Wäsch, Martin Schumacher, Monika Engelhardt

Blood (2012) 120 (21): 4982.

https://doi.org/10.1182/blood.V120.21.4982.4982

Published: 2012

Journal Articles

Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks

Jennifer M. Yeh, Lisa Diller

Blood (2012) 120 (11): 2195–2202.

https://doi.org/10.1182/blood-2012-02-409821

Published: 2012

Includes: Supplemental data

Journal Articles

What Predicts Agreement about Prognosis Between Patients and Physicians?

Amy Sullivan, ScD, Stewart Alexander, PhD, Anthony Back, MD, Maureen Wilson-Genderson, PhD, Fausto R. Loberiza, Jr., MD, MS, James Tulsky, MD, Susan Block, MD, Stephanie J. Lee, MD, MPH

Blood (2011) 118 (21): 1021.

https://doi.org/10.1182/blood.V118.21.1021.1021

Published: 2011

Journal Articles

The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

Chiara Lobetti-Bodoni, MD, Paola MV Rancoita, PhD, Silvia Montoto, MD, Armando Lopez-Guillermo, MD, Annarita Conconi, MD, Rita Coutinho, MD, Janet Matthews, Silvia Franceschetti, MD, Francesco Bertoni, MD, Franco Cavalli, MD, Michele Ghielmini, MD, Andrew Lister, MD, Emili Montserrat, MD, Emanuele Zucca, MD

Blood (2011) 118 (21): 1593.

https://doi.org/10.1182/blood.V118.21.1593.1593

Published: 2011

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Spero R Cataland, MD, Flora Peyvandi, MD, PhD, Pier M. Mannucci, MD, Bernhard Lämmle, Johanna A Kremer Hovinga, MD, Samuel J Machin, Marie Scully, Gail Rock, PhD, MD, FRCP, James Gilbert, MD, Paul Knoebl, Shangbin Yang, PhD, Haifeng Wu, M.D., Bernd Jilma, MD

Blood (2010) 116 (21): 726.

https://doi.org/10.1182/blood.V116.21.726.726

Published: 2010

NARROW

A Phase 1a/b Dose Escalation Study of Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

A Patient-Centred Approach to Understanding the Trade-Offs Associated with Treatment Decision Making in Hematological Cancers with Short Life Expectancy

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Life Expectancy in Long-Term Survivors Transplanted for Myelofibrosis: A Registry Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Risk Differential in Inhibitor Development in the First Days of Treatment By Product Class: A Sippet Analysis

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

"Post-Pulmonary Embolism Syndrome" after a First Episode of PE: Results of the E.L.O.P.E. Study

Quality of Life Survey in Nonmyeloablative Bone Marrow Transplant Patients at a Large Academic Center

Impact Of Dedicated CML Clinic On The Outcome Of Patients With Newly Diagnosed CML: Experience Of a Single Canadian Center

Individual Patient Data Of Conditional Survival Analysis In a Large Cohort Of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way To Identify Patients With Extended Life Expectancy

Estimating Long-Term Life Expectancy in Philadelphia Chromosome Positive (Ph+) Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results of A Microsimulation Model

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy

Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks

What Predicts Agreement about Prognosis Between Patients and Physicians?

The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only